keyword
MENU ▼
Read by QxMD icon Read
search

Asbergers

keyword
https://www.readbyqxmd.com/read/28223082/negative-emotions-and-suicidal-ideation-during-psychosocial-treatments-in-older-adults-with-major-depression-and-cognitive-impairment
#1
Dimitris N Kiosses, James J Gross, Samprit Banerjee, Paul R Duberstein, David Putrino, George S Alexopoulos
OBJECTIVE: To examine the relationship of negative emotions with suicidal ideation during 12 weeks of Problem Adaptation Therapy (PATH) versus Supportive Therapy of Cognitively Impaired Older Adults (ST-CI), hypothesizing that improved negative emotions are associated with reduced suicidal ideation, PATH improves negative emotions more than ST-CI, and improved negative emotions, rather than other depression symptoms, predict reduction in suicidal ideation. METHODS: In a randomized controlled trial of two home-delivered psychosocial interventions, 74 older participants (65-95 years old) with major depressive disorder and cognitive impairment were recruited in collaboration with community agencies...
January 19, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28222439/trajectories-of-depression-in-late-life-a-1-year-follow-up-study
#2
Tom Borza, Knut Engedal, Sverre Bergh, Jūratė Šaltytė Benth, Geir Selbæk
AIMS: To investigate the prognosis of depression in late life (DLL) in terms of the course of depression over 1 year and assess clinical factors related to the prognosis. METHODS: We performed an observational, multicenter, longitudinal study of 160 patients aged ≥60 years who were admitted to inward treatment of DLL. The patients were followed with 3 assessments: at inclusion (T0), at discharge from the hospital (T1), and after 1 year (T2). Growth mixture modeling was applied to identify patient classes following distinct trajectories of the Montgomery-Åsberg Depression Rating Scale (MADRS) score...
February 22, 2017: Dementia and Geriatric Cognitive Disorders
https://www.readbyqxmd.com/read/28213121/determination-of-a-clinically-important-difference-and-definition-of-a-responder-threshold-for-the-ucsd-performance-based-skills-assessment-upsa-in-patients-with-major-depressive-disorder
#3
Philip D Harvey, William Jacobson, Wei Zhong, George G Nomikos, Christina Kurre Olsen, Elizabeth Merikle, Michael Cronquist Christensen
BACKGROUND: This article reports an evaluation of the psychometric properties and clinically important difference (CID) threshold of the UCSD Performance-Based Skills Assessment (UPSA) in major depressive disorder (MDD), using data from a large-scale study of the effects of vortioxetine on cognitive functioning and functional capacity in MDD patients. METHODS: Adults with moderate-to-severe recurrent MDD and self-reported cognitive dysfunction were randomized to 8 weeks of double-blind treatment with vortioxetine 10/20mg QD (flexible), duloxetine 60mg QD, or placebo...
February 14, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28177953/double-blind-switch-study-of-vilazodone-in-the-treatment-of-major-depressive-disorder
#4
Jon E Grant, Sarah A Redden, Eric W Leppink
Approximately 40% of patients treated for depression do not respond to a trial of an antidepressant. The aim of the proposed study was to evaluate the efficacy and safety of switching to vilazodone in patients with major depressive disorder who are unresponsive or only partially responsive to a trial of citalopram. Seventy-nine adults with major depressive disorder were enrolled in an open-label study of citalopram (20 mg/day) for 6 weeks. Those still symptomatic after 6-weeks of citalopram were randomly assigned to either a higher dose of citalopram (40 mg/day) or to vilazodone in a double-blind trial for 6 weeks...
February 7, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28169581/gray-matter-trophism-cognitive-impairment-and-depression-in-patients-with-multiple-sclerosis
#5
Emanuele Pravatà, Maria A Rocca, Paola Valsasina, Gianna C Riccitelli, Claudio Gobbi, Giancarlo Comi, Andrea Falini, Massimo Filippi
BACKGROUND: Cognitive impairment and depression frequently affects patients with multiple sclerosis (MS). However, the relationship between the occurrence of depression and cognitive impairment and the development of cortical atrophy has not been fully elucidated yet. OBJECTIVES: To investigate the association of cortical and deep gray matter (GM) volume with depression and cognitive impairment in MS. METHODS: Three-dimensional (3D) T1-weighted scans were obtained from 126 MS patients and 59 matched healthy controls...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28152174/depression-case-finding-in-individuals-with-dementia-a-systematic-review-and-meta-analysis
#6
Zahra S Goodarzi, Bria S Mele, Derek J Roberts, Jayna Holroyd-Leduc
OBJECTIVES: To compare the diagnostic accuracy of depression case finding tools with a criterion standard in the outpatient setting among adults with dementia. DESIGN: Systematic review and meta-analysis. SETTING: Studies of older outpatients with dementia. PARTICIPANTS: Elderly outpatients (clinic and long-term care) with dementia (N = 3,035). MEASUREMENTS: Prevalence of major depression and diagnostic accuracy measures including sensitivity, specificity, and likelihood ratios...
February 2, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28146606/the-cyp3a-biomarker-4%C3%AE-hydroxycholesterol-does-not-improve-tacrolimus-dose-predictions-early-after-kidney-transplantation
#7
Elisabet Størset, Kristine Hole, Karsten Midtvedt, Stein Bergan, Espen Molden, Anders Åsberg
AIMS: Tacrolimus is a cornerstone in modern immunosuppressive therapy after kidney transplantation. Tacrolimus dosing is challenged by considerable pharmacokinetic variability, both between patients and over time after transplantation, partly due to variability in cytochrome P450 3A (CYP3A) activity. The aim of this study was to assess the value of the endogenous CYP3A marker 4β-hydroxycholesterol (4βOHC) for tacrolimus dose individualization early after kidney transplantation. METHODS: Data were obtained from 79 adult kidney transplant recipients who contributed a total of 625 4βOHC measurements and 1999 tacrolimus whole blood concentrations during the first two months after transplantation...
February 1, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28137247/a-randomised-controlled-trial-of-dietary-improvement-for-adults-with-major-depression-the-smiles-trial
#8
Felice N Jacka, Adrienne O'Neil, Rachelle Opie, Catherine Itsiopoulos, Sue Cotton, Mohammedreza Mohebbi, David Castle, Sarah Dash, Cathrine Mihalopoulos, Mary Lou Chatterton, Laima Brazionis, Olivia M Dean, Allison M Hodge, Michael Berk
BACKGROUND: The possible therapeutic impact of dietary changes on existing mental illness is largely unknown. Using a randomised controlled trial design, we aimed to investigate the efficacy of a dietary improvement program for the treatment of major depressive episodes. METHODS: 'SMILES' was a 12-week, parallel-group, single blind, randomised controlled trial of an adjunctive dietary intervention in the treatment of moderate to severe depression. The intervention consisted of seven individual nutritional consulting sessions delivered by a clinical dietician...
January 30, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28129308/comparison-of-the-efficacy-and-safety-of-aripiprazole-versus-bupropion-augmentation-in-patients-with-major-depressive-disorder-unresponsive-to-selective-serotonin-reuptake-inhibitors-a-randomized-prospective-open-label-study
#9
Eun-Jin Cheon, Kwang-Hun Lee, Young-Woo Park, Jong-Hun Lee, Bon-Hoon Koo, Seung-Jae Lee, Hyung-Mo Sung
PURPOSE: The purpose of this study was to compare the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder (MDD) unresponsive to selective serotonin reuptake inhibitors (SSRIs). METHODS: This is the first randomized, prospective, open-label, direct comparison study between aripiprazole and bupropion augmentation. Participants had at least moderately severe depressive symptoms after 4 weeks or more of SSRI treatment...
January 26, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28126706/sertraline-versus-placebo-in-patients-with-major-depressive-disorder-undergoing-hemodialysis-a-randomized-controlled-feasibility-trial
#10
Karin Friedli, Ayman Guirguis, Michael Almond, Clara Day, Joseph Chilcot, Maria Da Silva-Gane, Andrew Davenport, Naomi A Fineberg, Benjamin Spencer, David Wellsted, Ken Farrington
BACKGROUND AND OBJECTIVES: Depression is common in patients on hemodialysis, but data on the benefits and risks of antidepressants in this setting are limited. We conducted a multicenter, randomized, double-blind, placebo-controlled trial of sertraline over 6 months in patients on hemodialysis with depression to determine study feasibility, safety, and effectiveness. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients on hemodialysis at five United Kingdom renal centers completed the Beck Depression Inventory II...
February 7, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28121336/reduction-in-retained-activity-participation-is-associated-with-depressive-symptoms-3-months-after-mild-stroke-an-observational-cohort-study
#11
Tamara Tse, Jacinta Douglas, Primrose Lentin, Thomas Lindén, Leonid Churilov, Henry Ma, Stephen Davis, Geoffrey Donnan, Leeanne M Carey
OBJECTIVE: To quantify the association of depressive symptoms with retained activity participation 3 months post-stroke, after adjusting for neurological stroke severity and age. DESIGN: A cross-sectional observational study of retained activity participation and depressive symptoms in stroke survivors with ischaemic stroke. PARTICIPANTS: One hundred stroke survivors with mild neurological stroke severity. METHODS: One hundred stroke survivors were recruited from 5 metropolitan hospitals and reviewed at 3 months post-stroke using measures of activity participation, Activity Card Sort-Australia, and depressive symptoms, Montgomery-Asberg Depression Rating Scale Structured Interview Guide (MADRS-SIGMA)...
January 31, 2017: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/28103816/use-of-a-self-rating-scale-to-monitor-depression-severity-in-recurrent-gp-consultations-in-primary-care-does-it-really-make-a-difference-a-randomised-controlled-study
#12
C Wikberg, J Westman, E-L Petersson, M E H Larsson, M André, R Eggertsen, J Thorn, H Ågren, C Björkelund
BACKGROUND: Little information is available about whether the use of self-assessment instruments in primary care affects depression course and outcome. The purpose was to evaluate whether using a depression self-rating scale in recurrent person-centred GP consultations affected depression severity, quality of life, medication use, and sick leave frequency. METHODS: Patients in the intervention group met their GP regularly at least 4 times during the 3 months intervention...
January 19, 2017: BMC Family Practice
https://www.readbyqxmd.com/read/28097909/administration-of-ketamine-for-unipolar-and-bipolar-depression
#13
Christoph Kraus, Ulrich Rabl, Thomas Vanicek, Laura Carlberg, Ana Popovic, Marie Spies, Lucie Bartova, Gregor Gryglewski, Konstantinos Papageorgiou, Rupert Lanzenberger, Matthäus Willeit, Dietmar Winkler, Janusz K Rybakowski, Siegfried Kasper
OBJECTIVE: Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile. METHODS: Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science. RESULTS: Randomized, placebo-controlled or open-label trials reported antidepressant response rates after 24 h on primary outcome measures at 61%...
March 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28093627/-validation-of-the-german-version-of-the-6%C3%A2-item-screener-brief-cognitive-test-with-broad-application-possibilities
#14
S Krupp, A Seebens, J Kasper, M Willkomm, F Balck
BACKGROUND: Especially during admission the detection of cognitive deficits relevant to everyday life should burden patient and examiner as little as possible. The 6‑item screener (SIS) takes approximately 1 min, is easy to learn, does not require any material and is independent of the patient's visual and fine motor skills. The test was first published in 2002 by Callahan who approved the present German translation. OBJECTIVE: We checked the convergent and discriminant validity, reliability and sensitivity to change of the German translation among geriatric patients...
January 16, 2017: Zeitschrift Für Gerontologie und Geriatrie
https://www.readbyqxmd.com/read/28092847/repetitive-transcranial-magnetic-stimulation-for-the-treatment-of-post-stroke-depression-a-systematic-review-and-meta-analysis-of-randomized-controlled-clinical-trials
#15
REVIEW
XinYi Shen, MingYi Liu, Yu Cheng, Cui Jia, XinYue Pan, QingYun Gou, XinLian Liu, Hui Cao, LuShun Zhang
BACKGROUND: Every year, more than fifteen million people worldwide experience a stroke, nearly 30% of stroke survivors are likely to experience post-stroke depression (PSD). Repetitive transcranial magnetic stimulation (rTMS) is one of the emerging techniques which assist in targeting rehabilitation after stroke. Although deterioration of PSD greatly affects the recovery and quality of life of stroke sufferers, the effect of rTMS therapy has not been systematically studied. OBJECTIVE: A systematic review and meta-analysis was conducted to determine the effect of rTMS on PSD...
March 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28086851/efficacy-of-intermittent-theta-burst-stimulation-itbs-and-10-hz-high-frequency-repetitive-transcranial-magnetic-stimulation-rtms-in-treatment-resistant-unipolar-depression-study-protocol-for-a-randomised-controlled-trial
#16
Samuel Bulteau, Veronique Sébille, Guillemette Fayet, Veronique Thomas-Ollivier, Thibault Deschamps, Annabelle Bonnin-Rivalland, Edouard Laforgue, Anne Pichot, Pierre Valrivière, Elisabeth Auffray-Calvier, June Fortin, Yann Péréon, Jean-Marie Vanelle, Anne Sauvaget
BACKGROUND: The treatment of depression remains a challenge since at least 40% of patients do not respond to initial antidepressant therapy and 20% present chronic symptoms (more than 2 years despite standard treatment administered correctly). Repetitive transcranial magnetic stimulation (rTMS) is an effective adjuvant therapy but still not ideal. Intermittent Theta Burst Stimulation (iTBS), which has only been used recently in clinical practice, could have a faster and more intense effect compared to conventional protocols, including 10-Hz high-frequency rTMS (HF-rTMS)...
January 13, 2017: Trials
https://www.readbyqxmd.com/read/28068788/a-double-blind-randomized-placebo-controlled-trial-of-lactobacillus-helveticus-and-bifidobacterium-longum-for-the-symptoms-of-depression
#17
Amy R Romijn, Julia J Rucklidge, Roeline G Kuijer, Chris Frampton
OBJECTIVES: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment response. METHOD: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8 weeks...
January 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28068779/norepinephrine-transporter-gene-variants-and-remission-from-depression-with-venlafaxine-treatment-in-older-adults
#18
Victoria S Marshe, Malgorzata Maciukiewicz, Soham Rej, Arun K Tiwari, Etienne Sibille, Daniel M Blumberger, Jordan F Karp, Eric J Lenze, Charles F Reynolds, James L Kennedy, Benoit H Mulsant, Daniel J Müller
OBJECTIVE: The primary objective of this study was to investigate five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission in depressed older adults treated with venlafaxine. A secondary objective was to analyze 17 other variants in serotonergic system genes (HTR1A, HTR2A, HTR1B, HTR2C, TPH1, TPH2) potentially involved in the mechanism of action of venlafaxine. METHOD: The sample included 350 adults age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on the Montgomery-Åsberg Depression Rating Scale (MADRS)...
January 10, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28068617/what-does-the-madrs-mean-equipercentile-linking-with-the-cgi-using-a-company-database-of-mirtazapine-studies
#19
Stefan Leucht, Hein Fennema, Rolf R Engel, Marion Kaspers-Janssen, Peter Lepping, Armin Szegedi
BACKGROUND: Little is known about the clinical relevance of the Montgomery Asberg Depression Rating Scale (MADRS) total scores. It is unclear how total scores translate into clinical severity, or how commonly used measures for response (reduction from baseline of ≥50% in the total score) translate into clinical relevance. Moreover, MADRS based definitions of remission vary. METHODS: We therefore compared: a/ the MADRS total score with the Clinical Global Impression - Severity Score (CGI-S) b/ the percentage and absolute change in the MADRS total scores with Clinical Global Impression - Improvement (CGI-I); c/ the absolute and percentage change in the MADRS total scores with CGI-S absolute change...
December 29, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28068615/effects-of-levomilnacipran-er-on-noradrenergic-symptoms-anxiety-symptoms-and-functional-impairment-in-adults-with-major-depressive-disorder-post-hoc-analysis-of-5-clinical-trials
#20
Pierre Blier, Carl Gommoll, Changzheng Chen, Kenneth Kramer
OBJECTIVE: To evaluate the effects of levomilnacipran extended-release (LVM-ER; 40-120mg/day) on noradrenergic (NA) and anxiety-related symptoms in adults with major depressive disorder (MDD) and explore the relationship between these symptoms and functional impairment. METHODS: Data were pooled from 5 randomized, double-blind, placebo-controlled trials (N=2598). Anxiety and NA Cluster scores were developed by adding selected item scores from the Montgomery-Åsberg Depression Rating Scale (MADRS) and 17-item Hamilton Depression Rating Scale (HAMD17)...
November 15, 2016: Journal of Affective Disorders
keyword
keyword
111401
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"